This article is more than 5 years old. Information may no longer be current.

First sustained-release DME treatment now available in Germany

Issue: June 2013

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

pSivida announced that Iluvien, the first sustained-release pharmaceutical for the treatment of chronic diabetic macular edema, has launched in Germany, and the first patient has been treated, according to a press release.

“We are very pleased Iluvien is now available in Germany, as well as for privately insured and private-pay patients in the U.K.,” Paul Ashton, PhD, president and CEO, said in the release. “We are also very pleased by Alimera’s resubmission of the [new drug application] for Iluvien to the FDA and the recently announced [Prescription Drug User Fee Act] goal date of Oct. 17, 2013.”

pSivida has a plan underway to investigate pivotal phase 3 clinical trials using the same micro-insert as Iluvien (sustained-release fluocinolone acetonide) for the treatment of posterior uveitis.